Clinical Trials Sponsored by Sanofi China

Total 8297 results

Sanofi

Completed

A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma

Neoplasm Malignant

United States
Sanofi

Completed

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey (EASE)

Type 2 Diabetes Mellitus

Turkey
Sanofi

Completed

Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease (ACCELA)

Intermittent Claudication

United States, France, Canada, Poland, Russian Federation, Austria, South Africa
Sanofi

Completed

Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial

Head and Neck Neoplasms

China
Sanofi

Completed

Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer (METRO-ABC)

Breast Cancer Metastatic

India
Sanofi

Completed

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (SORELLA1)

Type 1 Diabetes Mellitus

Japan, Spain, Germany, United States, France, Hungary, Poland, Russian Federation
Sanofi

Completed

Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia

Fever | Dengue Fever

Malaysia, Thailand, Indonesia, Philippines, Vietnam
Sanofi

Completed

Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis (ACCORD-RA)

Rheumatoid Arthritis

Romania, Russian Federation, Ukraine, Bulgaria, Slovakia, Croatia, Czechia
Sanofi

Terminated

Drotaverine in Dysmenorrhoea Treatment

Dysmenorrhea

Hungary
Sanofi

Completed

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (SARILNIUSATURN)

Uveitis

Italy, Turkey, Spain, United States, Czechia, France
Sanofi

Completed

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM (LixiLan-O)

Type 2 Diabetes

Australia, Denmark, South Africa, Spain, Belgium, Russian Federation, Canada, Estonia, Hungary, Latvia, Mexico, United States, Chile, Czech Republic, France, Germany, Italy, Lithuania, Poland, Romania, Sweden, Ukraine, United Kingdom
Sanofi

Completed

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (TOPIC)

Multiple Sclerosis

United States, Australia, Austria, Bulgaria, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Lithuania, Mexico, Poland, Romania, Russian Federation, Turkey, Ukraine, United Kingdom
Sanofi

Completed

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (GetGoal-Duo-2)

Type 2 Diabetes

United States, Canada, Chile, Czech Republic, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, Spain, Ukraine, United Kingdom
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-F1)

Diabetes Mellitus, Type 2

United States, Brazil, Poland, Romania, Ukraine, Germany, Italy, Estonia, Malaysia, Philippines, Mexico, Lithuania, Colombia, Slovakia, Chile
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO)

Diabetes Mellitus, Type 2

United States, Poland, Romania, Russian Federation, Ukraine, India, Belgium, Mexico, Tunisia, Japan, Israel, Korea, Republic of
Sanofi

Completed

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (TERI-PRO)

Multiple Sclerosis

Finland, Belgium, Spain, Chile, Norway, Italy, United States, Austria, Canada, France, Germany, Greece, Sweden, United Kingdom
Sanofi

Completed

Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo (AUTOMATIX)

Type 2 Diabetes Mellitus

Germany, United Kingdom
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (GETGOAL-P)

Diabetes Mellitus Type 2

United States, Austria, Canada, France, Germany, Greece, Guatemala, India, Mexico, Peru, Puerto Rico, Romania, Turkey
Sanofi

Completed

Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

Type 2 Diabetes Mellitus

Spain, United States, Canada, Czech Republic, France, Germany, Poland, Romania, Russian Federation, Ukraine
Sanofi

Completed

Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

Type 2 Diabetes Mellitus

Germany
Sanofi

Completed

Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (GetGoal-M-Asia)

Type 2 Diabetes Mellitus

China, Hong Kong, Malaysia, Thailand
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) (GETGOAL-L-ASIA)

Diabetes Mellitus, Type 2

Philippines, Taiwan, Japan, Korea, Republic of
Sanofi

Completed

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (GetGoal-Duo1)

Type 2 Diabetes Mellitus

United States, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, South Africa, Swed... and more
Sanofi

Completed

Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Open Label, Phase I ZD6474 Head and Neck Cancer Study

Head and Neck Cancer

United States
Sanofi

Terminated

Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases

Non-small Cell Lung Cancer (NSCLC)

Netherlands
Sanofi

Completed

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

Type 1 Diabetes Mellitus

United States
Sanofi

Completed

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

Malignant Solid Tumor - Malignant Nervous System Neoplasm

United States, Canada
Sanofi

Terminated

Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)

Ulcerative Colitis

United States
Sanofi

Completed

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

Multiple Sclerosis

Belgium, United States, Australia, Austria, Belarus, Canada, Chile, China, Czech Republic, Estonia, France, Germany, Greece, Mexico, Netherlands, Philippines, Poland, Romania, Slovakia, Spain, Sweden, Thailand, Tunisia, Turkey, Ukraine, United...
Sanofi

Completed

Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases (EPLID)

Hepatic and Hepatobiliary Disorders

Russian Federation
Sanofi

Terminated

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug (SYMPHONY)

Obesity | Diabetes Mellitus Type 2

Japan
Sanofi

Completed

Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen (PAPRIKA)

Pancreatic Neoplasms

United States, Brazil, Poland, Russian Federation, Germany, Turkey, India, Belgium, Czech Republic, Mexico, Chile, Finland, Hungary, Italy, Norway, Canada, Colombia, Peru, Slovakia, Spain, United Kingdom
Sanofi

Completed

Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer

Prostate Cancer Metastatic

India
Sanofi

Completed

Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death (ALPHEE)

Ventricular Arrhythmia | Arrhythmia Prophylaxis

Netherlands, Spain, Belgium, Japan, Finland, Chile, Australia, United States, Argentina, Canada, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Mexico, Norway, Poland, Portugal, Russian Federation, Slovakia, South Africa and more
Sanofi

Terminated

Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus (SAMS)

Sleep Initiation and Maintenance Disorders

United States, Canada, Brazil, Russian Federation, Australia, Germany, Italy, Spain, Turkey, India, Malaysia, Singapore, Belgium, Czech Republic, Mexico, Argentina, Austria, Colombia, Chile, South Africa, United Kingdom, Hong Kong
Sanofi

Terminated

Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver (SPARe-1)

Liver Cirrhosis | Ascites

France, Canada, Romania, Australia, Germany, Italy, Portugal, Spain, Bulgaria, Malaysia, Serbia, Singapore, Taiwan, Belgium, Czech Republic, Croatia, Hungary, Israel, United Kingdom, Korea, Republic of, South Africa, United States, ... and more
Sanofi

Completed

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

Depressive Disorder

United States, France, Russian Federation, Sweden, Turkey, Czech Republic, Mexico, Croatia
Sanofi

Completed

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

Major Depressive Disorder

United States, France, Sweden, Mexico, Argentina, Finland
Sanofi

Terminated

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant (AUDITOR)

Arteriosclerosis | Obesity | Carotid Artery Plaque | Metabolic Syndrome X

United States, France, Canada, Netherlands, Spain, United Kingdom
Sanofi

Completed

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

Diabetes Mellitus, Insulin-Dependent

United States
Sanofi

Terminated

Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes (RAPSODI)

Prediabetic State

United States
Sanofi

Terminated

Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes (TOCCATA)

Diabetes Mellitus, Type 2

United States, Poland, Romania, Russian Federation, Ukraine, Malaysia, Philippines, Taiwan, Mexico, Lithuania, Slovakia, Indonesia, Thailand
Sanofi

Completed

Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin

Type 2 Diabetes Mellitus

Russian Federation
Sanofi

Terminated

Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia

Hypercholesterolemia

United States, Puerto Rico
Sanofi

Terminated

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes (ALLEGRO)

Diabetes Mellitus, Type 2

United States, Romania, Russian Federation, Spain, Sweden, India, Mexico, Denmark, Finland, Hungary, Italy, Korea, Republic of, Chile, Puerto Rico
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

Influenza | Myxovirus Infection

United States
Sanofi

Completed

Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer (CILAB)

Urinary Bladder Neoplasms

Belgium, Mexico, Brazil, Chile, Poland, South Africa, Spain, Israel, United States, Argentina, Australia, Canada, France, India, Italy, Netherlands, Russian Federation, Sweden, Turkey
Sanofi

Terminated

Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line

Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)

Hungary
Sanofi

Completed

Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients

Systemic Lupus Erythematosus

Germany

Clinical Trials Sponsored by Sanofi China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations